Atlas Brown,Inc. Bristol Myers Squibb CO Transaction History

Atlas Brown,Inc.

$325 Million
Q4 2025

A detailed history of Atlas Brown,Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Atlas Brown,Inc. holds 13,474 shares of BMY stock, worth $630,717. This represents 0.19% of its overall portfolio holdings.

Number of Shares

13,474

Previous 16,163 16.64%

Holding current value

$630,717

Previous $728,000 13.46%

% of portfolio

0.19%

Previous 0.22%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 09, 2026	SELL	$42.6 - $49.08 $114,551 - $131,976	-2,689 Reduced 16.64%	13,474 $630,000
Q3 2025 Oct 17, 2025	SELL	$43.31 - $48.98 $649 - $734	-15 Reduced 0.09%	16,163 $728,000
Q2 2025 Jul 08, 2025	SELL	$44.12 - $59.6 $2,647 - $3,576	-60 Reduced 0.37%	16,178 $748,000
Q1 2025 Apr 08, 2025	SELL	$53.9 - $63.11 $17,301 - $20,258	-321 Reduced 1.94%	16,238 $990,000
Q4 2024 Jan 10, 2025	BUY	$51.92 - $59.94 $26,894 - $31,048	518 Added 3.23%	16,559 $936,000

Q3 2024 Oct 18, 2024	SELL	$39.66 - $51.75 $70,713 - $92,270	-1,783 Reduced 10.0%	16,041 $830,000
Q2 2024 Jul 23, 2024	BUY	$40.25 - $52.99 $1,167 - $1,536	29 Added 0.16%	17,824 $740,000
Q1 2024 Apr 08, 2024	SELL	$47.98 - $54.4 $12,906 - $14,633	-269 Reduced 1.49%	17,795 $965,000
Q4 2023 Jan 18, 2024	SELL	$48.48 - $57.85 $11,926 - $14,231	-246 Reduced 1.34%	18,064 $926,000
Q3 2023 Oct 17, 2023	SELL	$57.89 - $64.73 $118,963 - $133,020	-2,055 Reduced 10.09%	18,310 $1.06 Million
Q2 2023 Jul 18, 2023	BUY	$63.71 - $70.74 $4,778 - $5,305	75 Added 0.37%	20,365 $1.3 Million
Q1 2023 Apr 21, 2023	BUY	$65.71 - $74.53 $12,090 - $13,713	184 Added 0.92%	20,290 $1.41 Million
Q4 2022 Jan 05, 2023	SELL	$68.48 - $81.09 $18,695 - $22,137	-273 Reduced 1.34%	20,106 $0
Q3 2022 Oct 06, 2022	BUY	$0.13 - $76.84 $6 - $3,611	47 Added 0.23%	20,379 $1.45 Million
Q2 2022 Jul 15, 2022	BUY	$72.62 - $79.98 $14,596 - $16,075	201 Added 1.0%	20,332 $1.57 Million
Q1 2022 Apr 14, 2022	SELL	$61.48 - $73.72 $18,136 - $21,747	-295 Reduced 1.44%	20,131 $1.47 Million
Q4 2021 Jan 18, 2022	BUY	$53.63 - $62.52 $58,081 - $67,709	1,083 Added 5.6%	20,426 $1.27 Million
Q3 2021 Oct 14, 2021	BUY	$59.17 - $69.31 $118 - $138	2 Added 0.01%	19,343 $1.15 Million
Q2 2021 Jul 19, 2021	BUY	$61.91 - $67.42 $148,026 - $161,201	2,391 Added 14.11%	19,341 $1.29 Million
Q1 2021 Apr 13, 2021	BUY	$59.34 - $66.74 $24,448 - $27,496	412 Added 2.49%	16,950 $1.07 Million
Q4 2020 Jan 19, 2021	SELL	$57.74 - $65.43 $17,148 - $19,432	-297 Reduced 1.76%	16,538 $1.03 Million
Q3 2020 Oct 15, 2020	BUY	$57.43 - $63.64 $114 - $127	2 Added 0.01%	16,835 $1.02 Million
Q2 2020 Jul 21, 2020	SELL	$54.82 - $64.09 $10,032 - $11,728	-183 Reduced 1.08%	16,833 $988,000
Q1 2020 Apr 16, 2020	BUY	$46.4 - $67.43 $104,168 - $151,380	2,245 Added 15.2%	17,016 $948,000
Q4 2019 Jan 14, 2020	BUY	$49.21 - $64.19 $241,276 - $314,723	4,903 Added 49.69%	14,771 $948,000
Q3 2019 Oct 29, 2019	BUY	$42.77 - $50.71 $34,344 - $40,720	803 Added 8.86%	9,868 $500,000
Q2 2019 Jul 24, 2019	BUY	$44.62 - $49.34 $62,557 - $69,174	1,402 Added 18.3%	9,065 $411,000
Q1 2019 Apr 12, 2019	SELL	$45.12 - $53.8 $4,376 - $5,218	-97 Reduced 1.25%	7,663 $366,000
Q4 2018 Jan 28, 2019	SELL	$48.76 - $63.23 $24,282 - $31,488	-498 Reduced 6.03%	7,760 $403,000
Q3 2018 Oct 26, 2018	SELL	$55.19 - $62.25 $176,497 - $199,075	-3,198 Reduced 27.92%	8,258 $513,000
Q2 2018 Jul 11, 2018	BUY	$50.53 - $62.98 $101 - $125	2 Added 0.02%	11,456 $644,000
Q1 2018 Apr 17, 2018	BUY	$59.92 - $68.98 $52,849 - $60,840	882 Added 8.34%	11,454 $724,000
Q4 2017 Jan 25, 2018	BUY	$59.94 - $65.35 $30,029 - $32,740	501 Added 4.97%	10,572 $674,000
Q3 2017 Oct 12, 2017	BUY	$55.23 - $63.74 $556,221 - $641,925	10,071	10,071 $642,000

Others Institutions Holding BMY

# of Institutions

2,720

Shares Held

1.58B

Call Options Held

28M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Brown,Inc., based on Form 13F filings with the SEC.

News

Stay updated on Atlas Brown,Inc. with notifications on news.

Account